Drug Approval | April 29, 2026
AbbVie seeks FDA nod for RINVOQ use in severe alopecia areata
After Phase 3 results show major hair regrowth gains
After Phase 3 results show major hair regrowth gains
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
The company reported consolidated total income of Rs. 161.3 crore in Q4 FY26, a strong jump from Rs. 120.3 crore in the same period last year
The company achieved 20% EBITDA profitability in Bengaluru and reached operational profitability across all its active cities
The submission is backed by positive results from the Phase 3 AFFIRM study
The centre will leverage AI-enabled tools to support research and diagnostics for complex eye–brain disorders
Collaboration to drive diagnostics exports, tap high-growth regional markets and build scalable commercialization platform
The webinar series will showcase next-gen imaging technologies, global expert insights, and hands-on sessions on microscopy innovations
At IIT Roorkee’s Vision 2047 conference, the union minister highlights BioE3 policy, rising biotech startups, and major scientific milestones
Subscribe To Our Newsletter & Stay Updated
